Cargando…
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential
Telomerase-based therapeutic cancer vaccines (TCVs) have been under clinical investigation for the past two decades. Despite past failures, TCVs have gained renewed enthusiasm for their potential to improve the efficacy of checkpoint inhibition. Telomerase stands as an attractive target for TCVs due...
Autores principales: | Ellingsen, Espen Basmo, Mangsbo, Sara M., Hovig, Eivind, Gaudernack, Gustav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288190/ https://www.ncbi.nlm.nih.gov/pubmed/34290704 http://dx.doi.org/10.3389/fimmu.2021.682492 |
Ejemplares similares
-
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma
por: Ellingsen, Espen Basmo, et al.
Publicado: (2023) -
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
por: Aamdal, Elin, et al.
Publicado: (2021) -
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022) -
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022) -
Personalized HLA typing leads to the discovery of novel HLA alleles and tumor‐specific HLA variants
por: Anzar, Irantzu, et al.
Publicado: (2022)